Modest Increase in Peak VO2 Is Related to Better Clinical Outcomes in Chronic Heart Failure PatientsClinical Perspective by Ann M. Swank, John Horton,

Slides:

Advertisements

Similar presentations

© 2010, American Heart Association. All rights reserved. A Validated Risk Score for In-hospital Mortality in Patients with Heart Failure from the American.

Advertisements

Efficacy and Safety of Exercise Training as a Treatment Modality in Patients With Chronic Heart Failure: Results of A Randomized Controlled Trial Investigating.

Post-discharge is a vulnerable phase for heart failure patients.

Flow Diagram of the Main HOPE Trial and the HOPE-TOO Trial Extension The HOPE and HOPE-TOO Trial Investigators JAMA. 2005;293:

SMMART-HF Surgery vs. Medical Treatment Alone for Patients with Significant MitrAl RegurgitaTion & Non-Ischemic Congestive Heart Failure Duke Heart Failure.

Treatment and Risk in Heart Failure: Gaps in Evidence or Quality? Pamela N. Peterson, MD MSPH; John S. Rumsfeld, MD PhD; Li Liang PhD; Adrian F. Hernandez,

New 2011 SHIFT quality of life substudy Quality of life ( QoL) in heart failure: where do we stand? Therapies that have survival benefits either have a.

Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Omega-3 Polyunsaturated Fatty Acids and Cardiovascular.

Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Beta-Blockers and Outcome in Heart Failure and Atrial.

Trends in Hospitalizations and Outcomes for Acute Cardiovascular Disease and Stroke, 1999–2011CLINICAL PERSPECTIVE by Harlan M. Krumholz, Sharon-Lise T.

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Making Sense of Statistics in Clinical Trial Reports:

Date of download: 7/10/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Evaluation Study of Congestive Heart Failure and.

Beyond the Laboratory by Julian P.J. Halcox, and John E. Deanfield Circulation Volume 109(21 suppl 1):II-42-II-48 June 1, 2004 Copyright © American Heart.

John W. Pickering, PhD, Matthew T. James, MD, PhD, FRCPC, Suetonia C

Ali Ahmed, MD, MPH, Gilbert J. Perry, MD, Jerome L. Fleg, MD, Thomas E

Admission heart rate and in-hospital outcomes in patients hospitalized for heart failure in sinus rhythm and in atrial fibrillation Anh L. Bui, MD, Maria.

by Hiroyuki Morita, and Issei Komuro

Circ Cardiovasc Qual Outcomes

by Adam J. Singer, Robert H

Circ Cardiovasc Qual Outcomes

Forecasting the Impact of Heart Failure in the United States

Three-dimensional Mapping of the Initiation of Nonsustained Ventricular Tachycardia in the Human Heart by Mina K. Chung, Steven M. Pogwizd, Dave P. Miller,

B-Type Natriuretic Peptide Testing and the Accuracy of Heart Failure Diagnosis in the Emergency DepartmentCLINICAL PERSPECTIVE by Amaali Lokuge, Louisa.

Tetsuro Tsujimoto, Hiroshi Kajio International Journal of Cardiology

Atrial Fibrillation and Mortality in Heart FailureClinical Perspective

Six-month–adjusted survival after aortic valve replacement (AVR) for severe aortic stenosis (AS) stratified by procedure and preoperative ejection fraction.

by Holly R. Middlekauff Circ Heart Fail Volume 3(4): July 20, 2010

Plasma Vitamin C, but Not Vitamin E, Is Associated With Reduced Risk of Heart Failure in Older MenClinical Perspective by Sasiwarang Goya Wannamethee,

Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure by Benjamin W. Van Tassell, Justin Canada, Salvatore Carbone, Cory Trankle, Leo.

Circ Cardiovasc Qual Outcomes

Site Selection and Performance in Clinical Trials

Plasma Free Fatty Acids and Risk of Heart FailureClinical Perspective

by Thomas Monks, Martin Pitt, Ken Stein, and Martin James

Influence of Cardiac Surgeon Report Cards on Patient Referral by Cardiologists in New York State After 20 Years of Public Reporting by David L. Brown,

Contribution of Stroke to the Cochrane Stroke Group Trials Register

Effect of Provider Volume on the Accuracy of Hospital Report Cards

Circ Arrhythm Electrophysiol

Circ Cardiovasc Qual Outcomes

by Gregg C. Fonarow, Clyde W. Yancy, Nancy M. Albert, Anne B

Prognostic Value of Changes in Galectin-3 Levels Over Time in Patients With Heart FailureClinical Perspective by A. Rogier van der Velde, Lars Gullestad,

Randomized Clinical Trial of Therapeutic Exercise in Subacute Stroke

Risk of Heart Failure Among Postmenopausal WomenCLINICAL PERSPECTIVE

O’Connor Efficacy and Safety of Exercise Training as a Treatment Modality in Patients With Chronic Heart Failure: Results of A Randomized Controlled.

Arterial Stiffness, Central Pressures, and Incident Hospitalized Heart Failure in the Chronic Renal Insufficiency Cohort StudyCLINICAL PERSPECTIVE by Julio.

Effects of Mineralocorticoid Receptor Antagonists on the Risk of Sudden Cardiac Death in Patients With Left Ventricular Systolic DysfunctionClinical Perspective.

Body Mass Index and Heart Failure Among Patients With Type 2 Diabetes MellitusCLINICAL PERSPECTIVE by Weiqin Li, Peter T. Katzmarzyk, Ronald Horswell,

Resting Ventricular–Vascular Function and Exercise Capacity in Heart Failure With Preserved Ejection FractionCLINICAL PERSPECTIVE by Selma F. Mohammed,

Optimal Pacing for Right Ventricular and Biventricular Devices

Circ Cardiovasc Interv

Circ Cardiovasc Interv

Nancy M. Albert, PhD, Gregg C. Fonarow, MD, William T

Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

BAT for HFrEF Trial design: Patients with chronic systolic HF were randomized in a 1:1 fashion to either baroreceptor activation therapy (BAT) or control.

Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study Vasilios Papademetriou, MD, DSc, Eric.

Effects of tai chi mind-body movement therapy on functional status and exercise capacity in patients with chronic heart failure: A randomized controlled.

Tetsuro Tsujimoto, Hiroshi Kajio International Journal of Cardiology

Anaerobic threshold responder analysis

Iron Deficiency in Heart Failure

Volume 11, Issue 1, Pages xv-xvii (January 2015)

Peter E. Carson et al. JCHF 2015;3:

Receiver operating characteristic curves for the association of primary outcome using each clinical risk score and each clinical risk score adjusted for.

Kaplan-Meier curves showing the time in months to the first inappropriate shock from the start of remote monitoring in primary and secondary prevention.

Marrick L. Kukin, MD Mayo Clinic Proceedings

Kaplan-Meier curve of cumulative percentage of cardiac mortality by peak flow rate category (adjusted HRs (95% CI) compared with ≥550 L/min: (

Steven R. Steinhubl, and Eric J. Topol JACC 2015;66:

Examples of ventilatory efficiency slope (minute ventilation (V′E)/carbon dioxide production (V′CO2) slope) in a healthy subject (green line) and a patient.

Kaplan-Meier plot for the prespecified primary endpoint (CARE-HF (A) and the secondary composite endpoint (all-cause mortality and new onset heart failure.

Effect of sacubitril/valsartan on the rate of primary end point and component and all-cause mortality in patients randomised in the PARADIGM-HF trial according.

Comparison of heart failure admissions rates per annum (recorded hospital admissions/ population at risk) in western developed countries 1978 to.

Kaplan-Meier curves showing the probability of symptom-free survival according to the rate of heart rate rise during exercise testing in (A) for the whole.

Presentation transcript:

Modest Increase in Peak VO2 Is Related to Better Clinical Outcomes in Chronic Heart Failure PatientsClinical Perspective by Ann M. Swank, John Horton, Jerome L. Fleg, Gregg C. Fonarow, Steven Keteyian, Lee Goldberg, Gene Wolfel, Eileen M. Handberg, Dan Bensimhon, Marie-Christine Illiou, Marianne Vest, Greg Ewald, Gordon Blackburn, Eric Leifer, Lawton Cooper, and William E. Kraus Circ Heart Fail Volume 5(5):579-585 September 18, 2012 Copyright © American Heart Association, Inc. All rights reserved.

Flow of patients through Heart Failure and a Controlled Trial to Investigate Outcomes of Exercise Training (HF-ACTION) clinical trial. Flow of patients through Heart Failure and a Controlled Trial to Investigate Outcomes of Exercise Training (HF-ACTION) clinical trial. Ann M. Swank et al. Circ Heart Fail. 2012;5:579-585 Copyright © American Heart Association, Inc. All rights reserved.

Adjusted survival curves for the 1620 subjects who completed prerandomization and 3-month cardiopulmonary exercise (CPX) tests categorized by direction of changes in peak oxygen uptake (VO2) over time for the primary outcome of all-cause mortality or all-cause hospitalization and 3 secondary end points, including time to cardiovascular mortality or cardiovascular hospitalization, cardiovascular mortality or heart failure (HF) hospitalization, and all-cause mortality. Adjusted survival curves for the 1620 subjects who completed prerandomization and 3-month cardiopulmonary exercise (CPX) tests categorized by direction of changes in peak oxygen uptake (VO2) over time for the primary outcome of all-cause mortality or all-cause hospitalization and 3 secondary end points, including time to cardiovascular mortality or cardiovascular hospitalization, cardiovascular mortality or heart failure (HF) hospitalization, and all-cause mortality. Ann M. Swank et al. Circ Heart Fail. 2012;5:579-585 Copyright © American Heart Association, Inc. All rights reserved.

Clinical algorithm relating change in peak oxygen uptake (VO2) from repeat cardiopulmonary exercise (CPX) testing to heart failure (HF) outcomes and therapy recommendations. Clinical algorithm relating change in peak oxygen uptake (VO2) from repeat cardiopulmonary exercise (CPX) testing to heart failure (HF) outcomes and therapy recommendations. Ann M. Swank et al. Circ Heart Fail. 2012;5:579-585 Copyright © American Heart Association, Inc. All rights reserved.